研究设计

Earthquake Insurance in California Pub Date : 2019-03-07 DOI:10.4324/9780429045790-4

R. Palm, M. Hodgson, R. Blanchard, D. Lyons

{"title":"研究设计","authors":"R. Palm, M. Hodgson, R. Blanchard, D. Lyons","doi":"10.4324/9780429045790-4","DOIUrl":null,"url":null,"abstract":"1Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, United States; 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria; 3Brigham and Women's Hospital, Boston, United States Results from a Two-part, Proof-of-concept, Dose-ranging, Multicenter, International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Of Sirukumab, a Human Anti-interleukin-6 Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy Disclosures","PeriodicalId":160962,"journal":{"name":"Earthquake Insurance in California","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Study Design\",\"authors\":\"R. Palm, M. Hodgson, R. Blanchard, D. Lyons\",\"doi\":\"10.4324/9780429045790-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"1Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, United States; 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria; 3Brigham and Women's Hospital, Boston, United States Results from a Two-part, Proof-of-concept, Dose-ranging, Multicenter, International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Of Sirukumab, a Human Anti-interleukin-6 Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy Disclosures\",\"PeriodicalId\":160962,\"journal\":{\"name\":\"Earthquake Insurance in California\",\"volume\":\"15 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Earthquake Insurance in California\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4324/9780429045790-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Earthquake Insurance in California","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4324/9780429045790-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

1Centocor Research & Development, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Malvern，美国分部;2维也纳医科大学和Hietzing医院，奥地利维也纳;一项两部分、概念验证、剂量范围、多中心、国际、随机、双盲、安慰剂对照的人类抗白细胞介素-6单克隆抗体Sirukumab在类风湿关节炎患者中的2期研究结果，尽管有甲氨蝶呤治疗的披露

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Study Design

1Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, United States; 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria; 3Brigham and Women's Hospital, Boston, United States Results from a Two-part, Proof-of-concept, Dose-ranging, Multicenter, International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Of Sirukumab, a Human Anti-interleukin-6 Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy Disclosures

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Earthquake Insurance in California

自引率

0.00%

发文量